Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-22

Clinical Trial Update: Psilocybin in Depression Resistant to Standard Treatments [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating psilocybin for treatment-resistant depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Psilocybin (psilocybin)

Snippet

Sponsor: King's College London | Conditions: Treatment Resistant Depression | Phase 2 | Status: UNKNOWN